The correct treatment for severe COVID-19 related sepsisis non-invasive ventilation, steroids, and

antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any beneft

whatsoever in rescuing critically-ill COVID-19 patients are antioxidants.

N-acetylcysteine, melatonin, fuvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants.

Indomethacin prevents iron- driven oxidation of arachidonic acid to isoprostanes. There are

powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet

which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore

oxygenation to the tissues.

Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known

or surmised much of this since March 2020. In April 2020, Swiss scientists confrmed that COVID-

19 was a vascular endotheliitis. By late 2020, experts had already concluded that COVID-19

causes a form of viral sepsis. They also know that sepsis can be efectively treated with

antioxidants. None of this information is particularly new, and yet, for the most part, it has not been

acted upon. Doctors continue to use damaging intubation techniques with high PEEP settings

despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients

with medical malpractice.

Because of the way they are constructed, Randomized Control Trials will never show any beneft

for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The

reason for this is simple; for the patients that they have recruited for these studies, such as

Oxford’s ludicrous RECOVERY study, the intervention is too late to have any positive efect.

The clinical course of COVID-19 is such that by the time most people seek medical attention for

hypoxia, their viral load has already tapered of to almost nothing. If someone is about 10 days

post-exposure and has already been symptomatic for fve days, there is hardly any virus left in their

bodies, only cellular damage and derangement that has initiated a hyperinfammatory response. It

is from this group that the clinical trials for antivirals have recruited, pretty much exclusively.

In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a

delayed hyperinfammatory response, and then absurdly claim that antivirals have no utility in

treating or preventing COVID-19. These clinical trials do not recruit people who are presymptomatic.

They do not test pre-exposure or post-exposure prophylaxis.